Cover Image

Cardiovascular and renal outcomes with empagliflozin in heart failure

Among patients with heart failure and a reduced ejection fraction, those who received the SGLT2 inhibitor empagliflozin had a significantly lower incidence of cardiovascular death or hospitalization for heart failure than those who received placebo.

Saved in:
Bibliographic Details
Main Authors: Packer, Milton (Author) , Anker, Stefan D. (Author) , Butler, Javed (Author) , Filippatos, Gerasimos (Author) , Pocock, Stuart J. (Author) , Carson, Peter (Author) , Januzzi, James (Author) , Verma, Subodh (Author) , Tsutsui, Hiroyuki (Author) , Brückmann, Martina (Author) , Jamal, Waheed (Author) , Kimura, Karen (Author) , Schnee, Janet (Author) , Zeller, Cordula (Author) , Cotton, Daniel (Author) , Bocchi, Edimar (Author) , Böhm, Michael (Author) , Choi, Dong-Ju (Author) , Chopra, Vijay (Author) , Chuquiure, Eduardo (Author) , Giannetti, Nadia (Author) , Janssens, Stefan (Author) , Zhang, Jian (Author) , Juanatey, Jose R. Gonzalez (Author) , Kaul, Sanjay (Author) , Rocca, Hans-Peter Brunner-La (Author) , Merkely, Bela (Author) , Nicholls, Stephen J. (Author) , Perrone, Sergio (Author) , Pina, Ileana (Author) , Ponikowski, Piotr (Author) , Sattar, Naveed (Author) , Senni, Michele (Author) , Seronde, Marie-France (Author) , Spinar, Jindrich (Author) , Squire, Iain (Author) , Taddei, Stefano (Author) , Wanner, Christoph (Author) , Zannad, Faiez (Author)
Format: Article (Journal)
Language:English
Published: October 8, 2020
In: The New England journal of medicine
Year: 2020, Volume: 383, Pages: 1413-1424
ISSN:1533-4406
DOI:10.1056/NEJMoa2022190
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1056/NEJMoa2022190
Verlag, lizenzpflichtig, Volltext: https://www.nejm.org/doi/full/10.1056/NEJMoa2022190
Get full text
Author Notes:Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Stuart J. Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann, Waheed Jamal, Karen Kimura, Janet Schnee, Cordula Zeller, Daniel Cotton, Edimar Bocchi, Michael Böhm, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure, Nadia Giannetti, Stefan Janssens, Jian Zhang, Jose R. Gonzalez Juanatey, Sanjay Kaul, Hans-Peter Brunner-La Rocca, Bela Merkely, Stephen J. Nicholls, Sergio Perrone, Ileana Pina, Piotr Ponikowski, Naveed Sattar, Michele Senni, Marie-France Seronde, Jindrich Spinar, Iain Squire, Stefano Taddei, Christoph Wanner, and Faiez Zannad for the EMPEROR-Reduced Trial Investigations
Description
Summary:Among patients with heart failure and a reduced ejection fraction, those who received the SGLT2 inhibitor empagliflozin had a significantly lower incidence of cardiovascular death or hospitalization for heart failure than those who received placebo.
Item Description:Gesehen am 07.02.2025
Physical Description:Online Resource
ISSN:1533-4406
DOI:10.1056/NEJMoa2022190

Similar Items